Tension Pneumomediastinum in Anti-MDA5 Antibody-positive Dermatomyositis-associated Interstitial Lung Disease: A Case Report and Literature Review
Intern Med. 2024 Apr 2. doi: 10.2169/internalmedicine.3418-23. Online ahead of print.ABSTRACTAnti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis (DM)-associated interstitial lung disease (ILD) can sometimes be complicated by pneumomediastinum, although tension pneumomediastinum is extremely rare. We herein report a case of anti-MDA5 antibody-positive DM-ILD that worsened subcutaneous and mediastinal emphysema during treatment. Hypotension and worsening respiratory failure were observed on day 20 of treatment. Mediastinal drainage under video-assisted thoracoscopic surgery promptly impro...
Source: Internal Medicine - April 3, 2024 Category: Internal Medicine Authors: Hiroko Okabayashi Seiya Nakashima Kosuke Fujino Miyu Imai Shohei Hamada Aiko Masunaga Hidenori Ichiyasu Makoto Suzuki Takuro Sakagami Source Type: research
Characteristics of chest high-resolution computed tomography in patients with anti-aminoacyl-tRNA synthetase antibody-positive interstitial lung disease
CONCLUSIONS: This retrospective study demonstrated that ARS-ILD patients, regardless of myositis symptoms, most often showed the NSIP pattern on HRCT, as previously reported. However, unlike previous reports, the UIP pattern on HRCT was not rare.PMID:38567566 | PMC:PMC11008333 | DOI:10.36141/svdld.v41i1.14144 (Source: Sarcoidosis Vasculitis and Diffuse Lung Diseases)
Source: Sarcoidosis Vasculitis and Diffuse Lung Diseases - April 3, 2024 Category: Respiratory Medicine Authors: Masato Mima Seidai Sato Takayoshi Shinya Nobuhito Naito Takatoshi Shoji Saki Harada Ryoko Suzue Kojin Murakami Kazuya Koyama Yasuhiko Nishioka Source Type: research
Baricitinib for anti-melanoma differentiation-associated protein 5 antibody-positive dermatomyositis-associated interstitial lung disease: a case series and literature review on Janus kinase inhibitors for the disease
AbstractAnti-melanoma differentiation-associated protein 5 antibody-positive dermatomyositis (anti-MDA5-DM) is frequently complicated by progressive interstitial lung disease (ILD), the prognosis of which is poor, and management is a major challenge. We treated three patients with anti-MDA5-DM-associated ILD (anti-MDA5-DM-ILD) using the Janus kinase (JAK) inhibitor, baricitinib, which improved lung opacities and saved two patients. We reviewed 6 patients with anti-MDA5-DM-ILD who had been treated with tofacitinib at our institution. Five of the patients survived, although discontinuation of tofacitinib due to complications...
Source: Rheumatology International - April 2, 2024 Category: Rheumatology Source Type: research
Successful treatment with tofacitinib for anti-melanoma differentiation-associated gene 5 antibody-positive juvenile dermatomyositis: case reports and review of the literature
We describe two female Japanese patients with anti-MDA5 Ab + JDM and rapidly progressive interstitial lung disease who achieved remission by adding tofacitinib to existing immunosuppressive drugs and present a literature review. While both patients received various immunosuppressive or anti-inflammatory treatments for induction therapy, remission could not be achieved. Subsequently, tofacitinib was administered to reduce the Krebs von den Lungen-6 level 5 months after diagnosis in one patient; the other patient received tofacitinib 4 months after diagnosis to reduce ferritin levels and skin manifestations. Subsequently, bo...
Source: Herpes - April 1, 2024 Category: Infectious Diseases Authors: Susumu Yamazaki Masaki Shimizu Ayane Yakabe Eisuke Inage Keisuke Jimbo Mitsuyoshi Suzuki Futaba Miyaoka Shuya Kaneko Hitoshi Irabu Asami Shimbo Yoshiyuki Ohtomo Masaaki Mori Tomohiro Morio Toshiaki Shimizu Source Type: research
Baricitinib for anti-melanoma differentiation-associated protein 5 antibody-positive dermatomyositis-associated interstitial lung disease: a case series and literature review on Janus kinase inhibitors for the disease
AbstractAnti-melanoma differentiation-associated protein 5 antibody-positive dermatomyositis (anti-MDA5-DM) is frequently complicated by progressive interstitial lung disease (ILD), the prognosis of which is poor, and management is a major challenge. We treated three patients with anti-MDA5-DM-associated ILD (anti-MDA5-DM-ILD) using the Janus kinase (JAK) inhibitor, baricitinib, which improved lung opacities and saved two patients. We reviewed 6 patients with anti-MDA5-DM-ILD who had been treated with tofacitinib at our institution. Five of the patients survived, although discontinuation of tofacitinib due to complications...
Source: Rheumatology International - March 30, 2024 Category: Rheumatology Source Type: research
Paraneoplastic Syndromes in Neuroendocrine Prostate Cancer: A Systematic Review
Curr Oncol. 2024 Mar 21;31(3):1618-1632. doi: 10.3390/curroncol31030123.ABSTRACTNeuroendocrine prostate cancer (NEPC) is a rare subtype of prostate cancer (PCa) that usually results in poor clinical outcomes and may be accompanied by paraneoplastic syndromes (PNS). NEPC is becoming more frequent. It can initially manifest as PNS, complicating diagnosis. Therefore, we reviewed the literature on the different PNS associated with NEPC. We systematically reviewed English-language articles from January 2017 to September 2023, identifying 17 studies meeting PRISMA guidelines for NEPC and associated PNS. A total of 17 articles we...
Source: Current Oncology - March 27, 2024 Category: Cancer & Oncology Authors: Mohammad Abufaraj Raghad Ramadan Amro Alkhatib Source Type: research
Paraneoplastic Syndromes in Neuroendocrine Prostate Cancer: A Systematic Review
Curr Oncol. 2024 Mar 21;31(3):1618-1632. doi: 10.3390/curroncol31030123.ABSTRACTNeuroendocrine prostate cancer (NEPC) is a rare subtype of prostate cancer (PCa) that usually results in poor clinical outcomes and may be accompanied by paraneoplastic syndromes (PNS). NEPC is becoming more frequent. It can initially manifest as PNS, complicating diagnosis. Therefore, we reviewed the literature on the different PNS associated with NEPC. We systematically reviewed English-language articles from January 2017 to September 2023, identifying 17 studies meeting PRISMA guidelines for NEPC and associated PNS. A total of 17 articles we...
Source: Current Oncology - March 27, 2024 Category: Cancer & Oncology Authors: Mohammad Abufaraj Raghad Ramadan Amro Alkhatib Source Type: research
